Methods for making proteins containing free cysteine residues

Details Methods for making proteins containing free cysteine residues Methods for making proteins containing free cysteine residues

2004-05-27

2009-12-08

Allen, Marianne P (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C530S402000

Reexamination Certificate

active

07629314

ABSTRACT:
The present invention relates to novel methods of making soluble proteins having free cysteines in which a host cell is exposed to a cysteine blocking agent. The soluble proteins produced by the methods can then be modified to increase their effectiveness. Such modifications include attaching a PEG moiety to form pegylated proteins.

REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 5166322 (1992-11-01), Shaw et al.
patent: 5206344 (1993-04-01), Katre et al.
patent: 5208158 (1993-05-01), Bech et al.
patent: 5223407 (1993-06-01), Wong et al.
patent: 5766897 (1998-06-01), Braxton
patent: 5849535 (1998-12-01), Cunningham et al.
patent: 5916773 (1999-06-01), Mele et al.
patent: 6780613 (2004-08-01), Wells et al.
patent: 7270809 (2007-09-01), Cox, III
patent: 7314921 (2008-01-01), Cox, III
patent: 7345154 (2008-03-01), Cox, III
patent: 2005/0096461 (2005-05-01), Cox, III
patent: 2008/0076706 (2008-03-01), Cox
patent: 0 185 459 (1986-06-01), None
patent: 0 312 358 (1989-04-01), None
patent: 0355460 (1990-02-01), None
patent: 0458064 (1991-11-01), None
patent: WO 90/12874 (1990-11-01), None
patent: WO 93/00109 (1993-01-01), None
patent: WO 93/06217 (1993-04-01), None
patent: WO 94/01453 (1994-01-01), None
patent: WO 94/12219 (1994-06-01), None
patent: WO 94/22466 (1994-10-01), None
patent: WO 95/11987 (1995-05-01), None
patent: WO 95/32003 (1995-11-01), None
patent: WO 96/31537 (1996-10-01), None
patent: WO 99/03887 (1999-01-01), None
patent: WO 00/42175 (2000-07-01), None
patent: WO 01/87925 (2001-11-01), None
Bil et al.,Biochimica et Biophysica Acta, 1261: 34-43 (1995).
Bittorf et al.,Febs. Lett., 366: 133-136 (1993).
Cheetham et al.,Nat. Structural Biol., 5: 861-866 (1998).
Dube et al.,The Journal of Biol. Chem., vol. 263, No. 33: 17516-17521 (1988).
Elliot et al.,Blood, 89:493-502 (1997).
Matthews et al.,PNAS, 93: 9471-9476(1996).
Syed et al.,Nature, 395:511-516, (1998).
Wen et al.,The Journal of Biol. Chem., vol. 269, No. 36: 22839-22846 (1994).
Clark et al.,J. Biol. Chem., 271(36):21969-21977 (1996).
Sytkowski et al.,Proc. Natl. Acad. Sci. USA, 95:1184-1188 (1998).
Bazan et al., Science, vol. 257 No. 5068, pp. 410-413 (Jul. 1992).
Bazan, Immunology Today, 11:350-354 (1990).
Boissel et al., J. Biol. Chem., 268(21):15983-15993 (1993).
Bowie et al., Science, vol. 247 No. 4948, pp. 1306-1310 (Mar. 1990).
Campbell et al., J. Peptide Res., 49:527-537 (1997).
Chern et al, “Structural role of amino acids 99-110 in recombinant human erythropoietin”, European Journal of Biochemistry, vol. 202 No. 2, pp. 225-229 (Dec. 1991).
Cunningham BC, Wells JA. Science. 244:1081-5, (1989).
Cunningham et al., Science, 243:1330-1336 (1989).
Fibi et al., “Evidence for the Location of the Receptor-Binding Site of Human Erythropoietin at the Carboxyl-Terminal Domain”, Blood, vol. 77, No. 6, Mar. 15, 1991; pp. 1203-1210.
Goodson and Katre, Bio/Technology, 8:343-346 (1990).
Grodberg et al., “Alanine scanning mutagenesis of humna erythropoietin identifies four amino acids which are critical for biological activity”, European Journal of Biochemistry, vol. 218, No. 2, pp. 597-601 (1993).
Lin et al., “Cloning and expression of the human erythropoietin gene”, Proceedings of the National Academy of Sciences, USA, vol. 82 No. 22, pp. 7580-7584 (Nov. 1985).
Mott and Campbell, Curr Opin Struct Biol, 5:114-121(1995).
Nielson et al., “Erythropoietin-beta-D-galactosidase. The generation, purification and use of a fusion protein”, Journal of Immunological Methods, vol. 111, No. 1, pp. 1-9 (Jun. 1988).
Olins P.O. et al: ‘Saturation muatgenesis of human interleukin-3’ Journal of Biological Chemistry vol. 270, No. 40, Oct. 6, 1996, pp. 23754-23760.
Quelle, “Phosphorylatable and epitope-tagged human erythropoietins: utility and purification of native baculovirus-derived forms” Protein Expr Purif, Dec. 1992; 3(6); 461-9, PubMed Abstract only, PMID 1283094.
Sprang and Bazan, Curr. Opin. Struct. Biol., 3:815-827 (1993).
Sytkowski et al, “Immunoshemical studies of human erythropoietin using site-specific anti-peptide antibodies”, Journal of Biological Chemistry, vol. 262, No. 3, pp. 1161-1165 (1987).
Weich et al., “Interleukin-3/erythropoietin fusion proteins: in vitro effects on hematopoietic cells”, Experimental Hematology, vol. 21, No. 5, pp. 647-655 (May 1993).
Wells, Ann. Rev. Biochem., 65:609-634 (1996).
Zalipsky, Adv. Drug Delivery Reviews, 16:157-182 (1995).
Zurawaki et al. “Definition and spatial location of mouse interleukin-2 residues that interact with the heterotrmeric receptor”, Embo Journal 12, 5113-5119, 1993.
Watson JD, Molecular biology of the Gene 3rd edition, p. 337, W. A. Benjamin, Inc. Menlo Park, California, Reading, Massachusetts, London, Amsterdam, Don Mills, Ontario. Sydney, 1977, ISBN 0-8053-9609-8.

Affiliated with

Also associated with

Rating

Methods for making proteins containing free cysteine residues does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for making proteins containing free cysteine residues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for making proteins containing free cysteine residues will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4083580